ParkinsonFranceV1, PubMed, Corpus, bibRecord, 000621

[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].

Identifieur interne : 000621 ( PubMed/Corpus ); précédent : 000620; suivant : 000622

[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].

Auteurs : M. Anheim

Source :

Revue neurologique [ 0035-3787 ] ; 2014.

RBID : pubmed:24581302

English descriptors

KwdEn :
- Clinical Trials, Phase I as Topic (trends), Clinical Trials, Phase II as Topic (trends), Dopamine (metabolism), France, Genetic Therapy (methods), Genetic Vectors (administration & dosage), Glutamate Decarboxylase (administration & dosage), Glutamate Decarboxylase (genetics), Humans, Infusions, Intraventricular, Parkinson Disease (genetics), Parkinson Disease (metabolism), Parkinson Disease (therapy), Pilot Projects, Putamen (metabolism), Putamen (pathology), United Kingdom.
MESH :
- chemical , administration & dosage : Glutamate Decarboxylase.
- chemical , genetics : Glutamate Decarboxylase.
- chemical , metabolism : Dopamine.
- administration & dosage : Genetic Vectors.
- genetics : Parkinson Disease.
- metabolism : Parkinson Disease, Putamen.
- methods : Genetic Therapy.
- pathology : Putamen.
- therapy : Parkinson Disease.
- trends : Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic.
- France, Humans, Infusions, Intraventricular, Pilot Projects, United Kingdom.

DOI: 10.1016/j.neurol.2014.02.002
PubMed: 24581302

Links to Exploration step

pubmed:24581302

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].</title>
<author><name sortKey="Anheim, M" sort="Anheim, M" uniqKey="Anheim M" first="M" last="Anheim">M. Anheim</name>
<affiliation><nlm:affiliation>Service de neurologie, unité des mouvements anormaux, Centre expert inter-régional de la maladie de Parkinson, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France. Electronic address: mathieu.anheim@chru-strasbourg.fr.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24581302</idno>
<idno type="pmid">24581302</idno>
<idno type="doi">10.1016/j.neurol.2014.02.002</idno>
<idno type="wicri:Area/PubMed/Corpus">000621</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000621</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].</title>
<author><name sortKey="Anheim, M" sort="Anheim, M" uniqKey="Anheim M" first="M" last="Anheim">M. Anheim</name>
<affiliation><nlm:affiliation>Service de neurologie, unité des mouvements anormaux, Centre expert inter-régional de la maladie de Parkinson, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France. Electronic address: mathieu.anheim@chru-strasbourg.fr.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Revue neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical Trials, Phase I as Topic (trends)</term>
<term>Clinical Trials, Phase II as Topic (trends)</term>
<term>Dopamine (metabolism)</term>
<term>France</term>
<term>Genetic Therapy (methods)</term>
<term>Genetic Vectors (administration & dosage)</term>
<term>Glutamate Decarboxylase (administration & dosage)</term>
<term>Glutamate Decarboxylase (genetics)</term>
<term>Humans</term>
<term>Infusions, Intraventricular</term>
<term>Parkinson Disease (genetics)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (therapy)</term>
<term>Pilot Projects</term>
<term>Putamen (metabolism)</term>
<term>Putamen (pathology)</term>
<term>United Kingdom</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Glutamate Decarboxylase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Glutamate Decarboxylase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Genetic Vectors</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
<term>Putamen</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Genetic Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Putamen</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Clinical Trials, Phase I as Topic</term>
<term>Clinical Trials, Phase II as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>France</term>
<term>Humans</term>
<term>Infusions, Intraventricular</term>
<term>Pilot Projects</term>
<term>United Kingdom</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24581302</PMID>
<DateCreated><Year>2014</Year>
<Month>03</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>11</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>170</Volume>
<Issue>2</Issue>
<PubDate><Year>2014</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Revue neurologique</Title>
<ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].</ArticleTitle>
<Pagination><MedlinePgn>89-90</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2014.02.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0035-3787(14)00711-5</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anheim</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Service de neurologie, unité des mouvements anormaux, Centre expert inter-régional de la maladie de Parkinson, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France. Electronic address: mathieu.anheim@chru-strasbourg.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType>
</PublicationTypeList>
<VernacularTitle>La thérapie tri-génique dans la maladie de Parkinson (ProSavin): vers une usine à dopamine putaminale?</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Rev Neurol (Paris)</MedlineTA>
<NlmUniqueID>2984779R</NlmUniqueID>
<ISSNLinking>0035-3787</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>EC 4.1.1.15</RegistryNumber>
<NameOfSubstance UI="D005968">Glutamate Decarboxylase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName>
<QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName>
<QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005968" MajorTopicYN="N">Glutamate Decarboxylase</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057967" MajorTopicYN="N">Infusions, Intraventricular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011699" MajorTopicYN="N">Putamen</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>01</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2014</Year>
<Month>01</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>01</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>3</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>3</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>11</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24581302</ArticleId>
<ArticleId IdType="pii">S0035-3787(14)00711-5</ArticleId>
<ArticleId IdType="doi">10.1016/j.neurol.2014.02.002</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000621 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000621 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:24581302
   |texte=   [Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:24581302" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].

[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki